Macrogen Inc (038290) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Macrogen Inc (038290) has a cash flow conversion efficiency ratio of 0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩7.10 Billion ≈ $4.81 Million USD) by net assets (₩168.36 Billion ≈ $114.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 038290 equity to assets ratio to measure how much of total assets are equity-financed.
Macrogen Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Macrogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 038290 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Macrogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Macrogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rimbunan Sawit Bhd
KLSE:5113
|
0.112x |
|
ALT5 Sigma Corporation
NASDAQ:ALTS
|
-0.014x |
|
NEOOTO Co. Ltd
KQ:212560
|
0.055x |
|
Morn Sun Feed Mill Corp
TWO:1240
|
0.045x |
|
South West Pinnacle Exploration Limited
NSE:SOUTHWEST
|
-0.016x |
|
Suny Cellular Communication Ltd
TA:SNCM
|
0.103x |
|
Mono Next Public Company Limited
BK:MONO
|
0.696x |
|
JEIO CO LTD (PROPOSED)
KQ:418550
|
0.000x |
Annual Cash Flow Conversion Efficiency for Macrogen Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Macrogen Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see 038290 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩177.43 Billion ≈ $120.24 Million |
₩7.12 Billion ≈ $4.83 Million |
0.040x | +34.13% |
| 2023-12-31 | ₩159.19 Billion ≈ $107.88 Million |
₩4.77 Billion ≈ $3.23 Million |
0.030x | -50.14% |
| 2022-12-31 | ₩179.32 Billion ≈ $121.52 Million |
₩10.77 Billion ≈ $7.30 Million |
0.060x | -43.13% |
| 2021-12-31 | ₩200.64 Billion ≈ $135.97 Million |
₩21.18 Billion ≈ $14.36 Million |
0.106x | +1.79% |
| 2020-12-31 | ₩198.15 Billion ≈ $134.28 Million |
₩20.55 Billion ≈ $13.93 Million |
0.104x | -18.91% |
| 2019-12-31 | ₩113.33 Billion ≈ $76.80 Million |
₩14.50 Billion ≈ $9.82 Million |
0.128x | -3.28% |
| 2018-12-31 | ₩118.01 Billion ≈ $79.98 Million |
₩15.61 Billion ≈ $10.58 Million |
0.132x | -4.58% |
| 2017-12-31 | ₩94.28 Billion ≈ $63.89 Million |
₩13.07 Billion ≈ $8.86 Million |
0.139x | -46.15% |
| 2016-12-31 | ₩82.55 Billion ≈ $55.94 Million |
₩21.25 Billion ≈ $14.40 Million |
0.257x | +173.79% |
| 2015-12-31 | ₩76.11 Billion ≈ $51.58 Million |
₩7.15 Billion ≈ $4.85 Million |
0.094x | -4.15% |
| 2014-12-31 | ₩67.13 Billion ≈ $45.49 Million |
₩6.58 Billion ≈ $4.46 Million |
0.098x | -35.74% |
| 2013-12-31 | ₩60.05 Billion ≈ $40.69 Million |
₩9.16 Billion ≈ $6.21 Million |
0.153x | -28.37% |
| 2012-12-31 | ₩51.71 Billion ≈ $35.05 Million |
₩11.02 Billion ≈ $7.47 Million |
0.213x | -17.57% |
| 2011-12-31 | ₩43.11 Billion ≈ $29.21 Million |
₩11.14 Billion ≈ $7.55 Million |
0.258x | -- |
About Macrogen Inc
Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing ser… Read more